Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hologic Inc Issues Q4 2013 Guidance Below Analysts' Estimates; Lowers FY 2013 Guidance


Monday, 5 Aug 2013 04:01pm EDT 

Hologic Inc announced that for the fourth quarter of 2013, it expects revenues of $615 million to $625 million and non--GAAP adjusted EPS of $0.36 to $0.37. This includes a reduction in EPS of $0.01 from the $6 million charge to earnings to write-off certain deferred financing costs and debt discount in connection with the $200 million voluntary prepayment of the Term B. For fiscal 2013, the Company is adjusting its fiscal 2013 non--GAAP revenues to a range of $2.505 billion to $2.515 billion (from a range of $2.53 billion to $2.55 billion) and non-GAAP EPS of $1.46 to $1.47 (from $1.54 to $1.56). This revised guidance also includes a $0.01 reduction in EPS in connection with the Term B prepayment. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $651 million and EPS of $0.44 for the fourth quarter of 2013; and revenue of $2.541 billion and EPS of $1.54 for fiscal 2013. 

Company Quote

25.59
0.36 +1.43%
23 Jul 2014